MedTrace Logo

Safety Study of Autologous Cultured Adipose -Derived Stem Cells for the Fecal Incontinence

NCT01011686 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2011-03-10

No results posted yet for this study

Summary

Fecal incontinence affects 18.4% adults in the community and greatly impacts quality of life. There's a problem like inconvenience, pain or allergic response in many therapeutic methods such as a surgical operation or material injection. ANT-SM is autologous adipose-derived stem cell, and so, expect of no immune responses. In this study, patients are given injection of ANT-AM in anal sphincter and followed for 4 weeks to test the safety.

Conditions

  • Fecal Incontinence

Interventions

BIOLOGICAL

ANT-SM

autologous adipose-derived stem cell

Sponsors & Collaborators

  • Anterogen Co., Ltd.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01011686 on ClinicalTrials.gov